STEM-Space™

Our scalable cellular manufacturing platform unlocks broad, reliable access to cell-based cures by uniting next-gen chemical reprogramming with natural HLA biology and biobanking.

3 Key Challenges With Current Cellular Programming

Unhealthy autologous patient cells yields poor quality of raw source material.

Focusing on cell type doesn’t capture rare cell subtypes affecting desired potency.

Lower rate of cell expansion limits manufacturing scale adding to high costs.

Allogeneic Cellular Manufacturing Platform

1. Scalable Next-Gen Stem Cell Reprogramming

Cell BioEngines accelerates the discovery and scalable development of cell therapies by chemically reprogramming the fate and function of clinical-grade HLA-homozygous cord blood stem cells using small molecules or biological agents, generating HAPLO-HSCs, HAPLO-IMX immune cells, and HAPLO-iPS cell products.

2. Precision Histocompatibility for Immune Integration

In a field constrained by autologous logistics and complex, heavily engineered allogeneic systems, our platform uses transgene-free, naturally HLA-matched homozygous products to reduce immune rejection without the need for multi-step genetic engineering.

3. Population-aligned Therapeutic Cell Biobank

Cell BioEngines differentiates itself through a clinically validated, population-guided HAPLO donor cord blood selection strategy that maximizes coverage and enables a therapeutic master cell biobank. While not fully universal, this approach represents a strategic middle ground—delivering a practical, genomically stable path to scalable, population-matched allogeneic therapies.

Platform Differentiation

Cord–derived healthy stem cell raw material
Inherent superior biological properties to deliver potent therapeutics
Clinically safe and genetically stable alternative
Off-the-shelf solution for rapid delivery within days
Scalable manufacturing of multiple doses from one cord unit
Improved dosing unit economics

Mapping the tumor microenvironment by single-cell genomics to reveal specialized population of immune cells amenable to therapeutic intervention.

Vishwakarma et al, Nature Communications Biology (2021)

Disruptive CGT technology assets under management

"We leverage the natural developmental biology of stem cells for large scale manufacturing. Each cord unit allows 10-100’s of doses per manufacturing run providing unparalleled scalability" - Founder & CEO, Dr. Ajay Vishwakarma

Learn more